Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition
Martijn A.J. Koppens (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Gergana Bounova (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Paulien Cornelissen-Steijger (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Nienke de Vries (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
Owen J. Sansom (Beatson Institute for Cancer Research)
L. F.A. Wessels (Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis, TU Delft - Pattern Recognition and Bioinformatics, Cancer Genomics Centre)
Maarten van Lohuizen (Cancer Genomics Centre, Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
EZH2 inhibitors have gained great interest for their use as anti-cancer therapeutics. However, most research has focused on EZH2 mutant cancers and recently adverse effects of EZH2 inactivation have come to light. To determine whether colorectal cancer cells respond to EZH2 inhibition and to explore which factors influence the degree of response, we treated a panel of 20 organoid lines derived from human colon tumors with different concentrations of the EZH2 inhibitor GSK126. The resulting responses were associated with mutation status, gene expression and responses to other drugs. We found that the response to GSK126 treatment greatly varied between organoid lines. Response associated with the mutation status of ATRX and PAX2, and correlated with BIK expression. It also correlated well with response to Nutlin-3a which inhibits MDM2-p53 interaction thereby activating p53 signaling. Sensitivity to EZH2 ablation depended on the presence of wild type p53, as tumor organoids became resistant when p53 was mutated or knocked down. Our exploratory study provides insight into which genetic factors predict sensitivity to EZH2 inhibition. In addition, we show that the response to EZH2 inhibition requires wild type p53. We conclude that a subset of colorectal cancer patients may benefit from EZH2-targeting therapies.